Home
/
Cartesian Therapeutics, Inc.
/
Financials
/
Quarterly
Cartesian Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cartesian Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$452.0K
Nov 6, 2025
Q2
2025
Jun 30, 2025
$298.0K
Aug 7, 2025
Q1
2025
Mar 31, 2025
$1.10M
May 8, 2025
Q3
2025
Sep 30, 2024
$387.0K
Nov 6, 2025
Q2
2025
Jun 30, 2024
$33.45M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$5.84M
May 8, 2025
Q3
2024
Sep 30, 2023
$6.55M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$5.25M
Aug 8, 2024
Q1
2018
Mar 31, 2018
$0
May 9, 2018
Q4
2017
Dec 31, 2017
$17.0K
Mar 15, 2018
Q4
2017
Sep 30, 2017
$27.0K
Mar 15, 2018
Q3
2017
Sep 30, 2017
$27.0K
Nov 7, 2017
Q2
2017
Jun 30, 2017
$26.0K
Aug 11, 2017
Q4
2017
Jun 30, 2017
$26.0K
Mar 15, 2018
Q4
2017
Mar 31, 2017
$137.0K
Mar 15, 2018
Q1
2018
Mar 31, 2017
$137.0K
May 9, 2018
Q4
2017
Dec 31, 2016
$2.93M
Mar 15, 2018
Q4
2017
Sep 30, 2016
$1.05M
Mar 15, 2018
Q3
2017
Sep 30, 2016
$1.05M
Nov 7, 2017
Q4
2017
Jun 30, 2016
$2.02M
Mar 15, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$0
Aug 7, 2025
Q1
2025
Mar 31, 2025
$400.0K
May 8, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$33.27M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$5.84M
May 8, 2025
Q3
2024
Sep 30, 2023
$6.55M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$5.25M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$5.94M
May 8, 2024
Q3
2023
Sep 30, 2022
$20.71M
Nov 13, 2023
Q2
2023
Jun 30, 2022
$39.27M
Aug 17, 2023
Q1
2023
Mar 31, 2022
$34.00M
May 4, 2023
Q3
2022
Sep 30, 2021
$24.43M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$19.66M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$11.05M
May 5, 2022
Q3
2021
Sep 30, 2020
$4.65M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$0
Aug 12, 2021
Q1
2021
Mar 31, 2020
$0
May 13, 2021
Q3
2020
Sep 30, 2019
$0
Nov 5, 2020
Q2
2020
Jun 30, 2019
$13.0K
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($35.90M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
$15.89M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$15.89M
Aug 7, 2025
Q2
2025
Mar 31, 2025
($17.71M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($17.71M)
May 8, 2025
Q3
2025
Mar 31, 2025
($17.71M)
Nov 6, 2025
Q3
2025
Sep 30, 2024
($24.18M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
$13.84M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$13.84M
Aug 7, 2025
Q1
2025
Mar 31, 2024
($56.82M)
May 8, 2025
Q2
2025
Mar 31, 2024
($56.82M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($56.82M)
Nov 6, 2025
Q3
2024
Sep 30, 2023
($9.00M)
Nov 7, 2024
Q3
2024
Jun 30, 2023
($11.39M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($11.39M)
Aug 8, 2024
Q2
2024
Mar 31, 2023
($21.66M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($21.66M)
May 8, 2024
Q3
2024
Mar 31, 2023
($21.66M)
Nov 7, 2024
Q3
2023
Sep 30, 2022
($7.89M)
Nov 13, 2023
Q3
2023
Jun 30, 2022
$8.60M
Nov 13, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($21.07M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($21.81M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($21.89M)
May 8, 2025
Q3
2025
Sep 30, 2024
($17.58M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$13.76M
Aug 7, 2025
Q1
2025
Mar 31, 2024
($13.35M)
May 8, 2025
Q3
2024
Sep 30, 2023
($13.07M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($18.64M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($18.38M)
May 8, 2024
Q3
2023
Sep 30, 2022
($1.60M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
$13.86M
Aug 17, 2023
Q1
2023
Mar 31, 2022
$10.77M
May 4, 2023
Q3
2022
Sep 30, 2021
($1.97M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
$452.0K
Aug 8, 2022
Q1
2022
Mar 31, 2021
($7.16M)
May 5, 2022
Q3
2021
Sep 30, 2020
($13.73M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($16.37M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($18.82M)
May 13, 2021
Q3
2020
Sep 30, 2019
($11.79M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($16.24M)
Aug 6, 2020